Guirguis-Blake J, et al. - The authors here aimed at determining the scope of and variation in prescribing relatively contraindicated medications and medications above the recommended dose levels among patients with stage III/IV chronic kidney disease (CKD) in primary care practice. They observed that primary care patients with stage III/IV CKD were frequently prescribed or had documented use of relatively contraindicated drugs. Thereby suggesting these patients be at risk of adverse drug events. In the USA, a significant number of individuals with CKD were noted, highlighting the necessity for a research that examines rates of adverse events related to these prescriptions and that tests primary care-based interventions to decrease inappropriate prescribing of relatively contraindicated medications to these patients.